Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

As of last trade Novo Nordisk A/S (NOVO B:CPH) traded at 950.90, -2.60% below its 52-week high of 976.30, set on Jan 04, 2023.
52-week range
620.70Feb 24 2022976.30Jan 04 2023
Markit short selling activity
Previous close941.50
Average volume1.72m
Shares outstanding1.74bn
Free float1.17bn
P/E (TTM)38.71
Market cap1.64tn DKK
EPS (TTM)24.32
Annual div (ADY)12.40
Annual div yield (ADY)1.32%
Div ex-dateAug 12 2022
Div pay-dateAug 16 2022
Next div ex-dateMar 24 2023
Next div pay-dateMar 28 2023
Data delayed at least 15 minutes, as of Feb 06 2023 10:34 GMT.
More ▼

Board of Directors


Sten Scheibye, Chairman of the Board


Göran A. Ando, Vice Chairman of the Board


Henrik Gürtler, Member of the Board


Ulrik Hjulmand-Lassen, Member of the Board (Employee Representative)


Pamela J Kirby, Member of the Board

Further Information

Investor Relations Contact

Klaus Bülow Davidsen
Head of Investor Relations
Corporate Vice President

Novo Allé
2880 Bagsværd

Tel: +45 4442 3176
Mobile: +45 3079 3176
Fax: +45 4444 6626
e-mail: klda@novonordisk.com

An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.